Company Overview and News
Investors in Molson Coors Brewing Co (NYSE:TAP) have to be disappointed so far this year. TAP stock is down more than 22% so far in 2018 and more than 27% over the past 12 months. This is compared to the 4.25% year-to-date gain in the SPDR S&P 500 ETF Trust (NYSEARCA:SPY). While Molson now yields 2.6%, investors have to be asking themselves if it’s time to pass on this brew and look for a more refreshing stock.
TAP STZ.B BUD STZ SAM DEO
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
NKTR TSRO SYY HUYA USFD KRC RGA AVGO MITL HST ABBV GE TAP EXPE PAY WIX EVLO TR SYBT ADDYY LBC WFC.PRL NFLX WFC.PRJ LB NVDA SKX GBTC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN LAYN AAPL BAH WFC.PRY INTC WFC.PRX WFC.PRW WFC.PRV TXMD SJM BLUE CASY SIX DDE TSLA AFSI UNH APTV ARE GVA AZN RL AFSS AMBA AFST UAL AFSI.PRC AFSI.PRB AFSI.PRA DNLI AFSI.PRF ARKW AFSI.PRE UHT AFSI.PRD IP NKE AMZN TWTR CATO CELG BLUE ARKK OSTK EQH BKE GWRE MAR CNDT LNC AHBIF ABBV WTM CURO WFCNP HRB SFIX MAR.WI ODT XYL BMY OBNK WFC H WFC.WS F BUD A COST PANW LNC.WS THO FUN ITRI W AZN BLK BKNG JNCE QTRX MRK FIVE
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED7!E+T=R;W5P+U,O5')A;G-P87)E;F-Y M+T-3+T1E=FEC95)'0CX^+U1A8G,O4R]3=')U8W1087)E;G1S(# ^/@T*96YD M;V)J#0HT(# @;V)J#0H\/"]&:6QT97(O1FQA=&5$96-O9&4O3&5N9W1H(#$U M,S(^/@T*
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
With the new inflation numbers coming in under expectations, that’s a bullish sign that the Federal Reserve won’t be adding more hikes to interest rates, at least for now.
TAP SJM IRBT CAG MHK 500570 TATAMOTORS TTM DF
Molson Coors Brewing Co (NYSE:TAP) stock was hit hard on Wednesday after releasing a poor earnings report for the first quarter of the year.
It has been a highly volatile earnings season thus far, as the market is punishing stocks for the slightest misstep. With this in mind, let’s take a quick look at three stocks that are falling sharply following their earnings releases:
TAP DBD SNAP
May 2, 2018: Here are four stocks trading with heavy volume among 97 equities making new 52-week lows in Wednesday’s session. On the NYSE decliners led advancers by about 8 to 7 and on the Nasdaq, advancers led decliners by about 5 to 4.
TAP T MDLZ SNAP
Document Use these links to rapidly review the document Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
7h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
8h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to TAP / Molson Coors Brewing Co. on message board site Silicon Investor.
as of ET